DE69943020D1 - Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs - Google Patents

Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs

Info

Publication number
DE69943020D1
DE69943020D1 DE69943020T DE69943020T DE69943020D1 DE 69943020 D1 DE69943020 D1 DE 69943020D1 DE 69943020 T DE69943020 T DE 69943020T DE 69943020 T DE69943020 T DE 69943020T DE 69943020 D1 DE69943020 D1 DE 69943020D1
Authority
DE
Germany
Prior art keywords
tmprss2
prostate
diagnosis
therapy
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69943020T
Other languages
English (en)
Inventor
Daniel E Afar
Rene S Hubert
Kahan Leong
Arthur B Raitano
Douglas C Saffran
Stephen Chappell Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Application granted granted Critical
Publication of DE69943020D1 publication Critical patent/DE69943020D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69943020T 1998-06-01 1999-06-01 Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs Expired - Lifetime DE69943020D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8759898P 1998-06-01 1998-06-01
US9147498P 1998-06-29 1998-06-29
US12952199P 1999-04-14 1999-04-14
PCT/US1999/012253 WO1999062942A2 (en) 1998-06-01 1999-06-01 Tumor antigen useful in diagnosis and therapy of prostate and colon cancer

Publications (1)

Publication Number Publication Date
DE69943020D1 true DE69943020D1 (de) 2011-01-20

Family

ID=27375711

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69943020T Expired - Lifetime DE69943020D1 (de) 1998-06-01 1999-06-01 Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs

Country Status (12)

Country Link
US (1) US20060275304A1 (de)
EP (1) EP1082341B1 (de)
JP (2) JP2002517185A (de)
AT (1) ATE490977T1 (de)
AU (2) AU773187B2 (de)
CA (1) CA2329137C (de)
CY (1) CY1111906T1 (de)
DE (1) DE69943020D1 (de)
DK (1) DK1082341T3 (de)
IL (1) IL139988A0 (de)
PT (1) PT1082341E (de)
WO (1) WO1999062942A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) * 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
WO2000020584A2 (en) * 1998-10-02 2000-04-13 Urogenesys, Inc. Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6
CA2347081A1 (en) * 1998-10-19 2000-04-27 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU4484400A (en) * 1999-04-23 2000-11-10 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
ATE420175T1 (de) 1999-08-12 2009-01-15 Agensys Inc C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen
EP1287029A2 (de) * 2000-06-09 2003-03-05 Corixa Corporation Zusammensetzungen und verfahren zur therapie und diagnose von dickdarmkrebs
EP1294903B1 (de) 2000-06-13 2008-05-07 Bayer HealthCare AG Regulierung einer humanen transmembran-serinprotease
ES2323407T3 (es) * 2000-07-12 2009-07-15 Agensys, Inc. Nuevo antigeno tumoral util en el diagnostico y terapia del cancer de vejiga, ovario, pulmon y riñon.
US6743592B1 (en) * 2000-07-25 2004-06-01 The Trustees Of The University Of Pennsylvania Methods, systems and kits for immuno-detection of epitopes expressed on molecules
US20040018973A1 (en) 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
WO2004092397A2 (en) * 2003-04-15 2004-10-28 Novartis Ag Tmprss2 regulatory sequences and uses thereof
WO2004097358A2 (en) * 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
CA2814598A1 (en) 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP2140022A2 (de) * 2007-03-30 2010-01-06 Oryzon Genomics, S.A. Nukleinsäureanalyseverfahren
ATE533861T1 (de) 2007-07-06 2011-12-15 Univ Michigan Mipol1-etv1-gen-neuanordnungen
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
JP5800817B2 (ja) 2009-09-17 2015-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
WO2013120929A1 (en) * 2012-02-15 2013-08-22 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
KR20170078677A (ko) 2014-11-06 2017-07-07 에프. 호프만-라 로슈 아게 Fcrn-결합이 개질된 fc-영역 변이체 및 이의 사용 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5288612A (en) * 1991-07-03 1994-02-22 The Scripps Research Institute Assay methods for detecting serum proteases, particularly activated protein C
WO1994016083A1 (en) * 1993-01-15 1994-07-21 Genetics Institute, Inc. Cloning of enterokinase and method of use
US6800746B2 (en) * 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1005546A2 (de) * 1997-02-25 2000-06-07 Corixa Corporation Verbindungen für die immuntherapie von prostatkrebs und verfahren zu deren verwendung
US6657056B2 (en) * 1997-02-25 2003-12-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
DK0972201T3 (da) * 1997-02-25 2006-01-02 Corixa Corp Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf
US20020119531A1 (en) * 1997-02-27 2002-08-29 Olga Bandman Prostate-associated protease antibody
US6043033A (en) * 1997-02-27 2000-03-28 Incyte Pharmaceuticals, Inc. Human prostate-associated protease
US20030103981A1 (en) * 1997-02-27 2003-06-05 Incyte Genomics, Inc. Methods of use of a prostate-associated protease in the diagnosis and treatment of prostate cancer
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
AU4839999A (en) * 1998-06-29 2000-01-17 Myriad Genetics, Inc. Tmprss2 is a tumor suppressor
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US6331427B1 (en) * 1999-03-26 2001-12-18 Millennium Pharmaceuticals, Inc. Protease homologs
US20020192763A1 (en) * 2000-04-17 2002-12-19 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US20020160382A1 (en) * 2000-10-11 2002-10-31 Lasek Amy W. Genes expressed in colon cancer
US20030065157A1 (en) * 2001-04-04 2003-04-03 Lasek Amy W. Genes expressed in lung cancer

Also Published As

Publication number Publication date
JP2009148265A (ja) 2009-07-09
CA2329137C (en) 2011-09-20
IL139988A0 (en) 2002-02-10
US20060275304A1 (en) 2006-12-07
AU2004202306C1 (en) 2008-05-01
WO1999062942A2 (en) 1999-12-09
JP2002517185A (ja) 2002-06-18
AU2004202306B2 (en) 2007-05-24
EP1082341B1 (de) 2010-12-08
AU2004202306A1 (en) 2004-06-24
CA2329137A1 (en) 1999-12-09
DK1082341T3 (da) 2011-03-28
ATE490977T1 (de) 2010-12-15
EP1082341A2 (de) 2001-03-14
WO1999062942A3 (en) 2000-06-02
AU4413699A (en) 1999-12-20
AU773187B2 (en) 2004-05-20
CY1111906T1 (el) 2015-11-04
PT1082341E (pt) 2011-02-15

Similar Documents

Publication Publication Date Title
CY1111906T1 (el) Αντιγονο ογκων χρησιμο για τη διαγνωση και θεραπεια καρκινου του προστατη και του παχεος εντερου
KR970702917A (ko) Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법, 치료 조성물, 항-이디오타입 항체
DE69434612D1 (de) Monoklonale Antikörper gegen recombinantes Stratum Corneum chymotryptisches Enzym (SCCE)
TR200101482T2 (tr) WT1'e özgü imünoterapi için bileşimler
AU1726199A (en) Metastatic cancer regulated gene
DK0772624T3 (da) Interleukin-15
ATE397062T1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
DE59101889D1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie.
US5698671A (en) Metalloproteinase peptides
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
ATE196775T1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
CY1109254T1 (el) Νεο αντιγονο ογκου χρησιμο στη διαγνωση και θεραπεια καρκινων της ουροδοχου κυστης, των ωοθηκων, του πνευμονα και του νεφρου
Dardik et al. The structure of endothelial cell thrombospondin: Characterization of the heparin‐binding domains
Barra et al. Primary structure of human copper-zinc superoxide dismutase. Cysteine-and tryptophan—Containing peptides
NO991653L (no) Immunogenisk tumor frigjorte partikler (TLP)-blanding
Durliat et al. Plasminogen receptors on rat colon carcinoma cells
DE69332583D1 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität
DE69900283D1 (de) Reninaktive Substanz enthaltend humanes Prorenin und Antikörper gegen das Prorenin Profragment
Ganea et al. A serine proteinase inhibitor produced by an HTLV I virus-transformed human T lymphocyte line.
ATE213773T1 (de) In apoptosis beteiligte cysteine protease cmh-1 und dns-sequenzen dafür
ATE402258T1 (de) Gene differentiell experimiert in brudtkrebs
AU2003222606A1 (en) Diagnosis of carcinoma using raigi polypeptides